Author details

Benelli Andrea\*, Vaccaro Chiara, Guzzo Sonia, Varca Virginia and Gregori Andrea Department of Urology, ASST Rhodense, G. Salvini Hospital, Milan, Italy

References

Clinicians. 2018;69:7-34

[1] Siegel R, Miller K, Jemal A. Cancer statistics, 2018. CA: A Cancer Journal for

DOI: http://dx.doi.org/10.5772/intechopen.85243

The Role of MRI-TRUS Fusion Biopsy in the Diagnosis of Clinical Significant…

recommendations for use. European

[10] Zhang L, Tang M, Chen S, et al. A meta-analysis of use of prostate imaging reporting and data system version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer. European Radiology. 2017;27(12):5204-5214

[11] Rosenkrantz A, Verma A, Choyke P, et al. Prostate magnetic resonance imaging and magnetic resonance

imaging targeted biopsy in patients with a prior negative biopsy: A consensus statement by AUA and SAR. The Journal

[12] Boesen L, Nørgaard N, Løgager V, et al. A prospective comparison of selective multiparametric magnetic resonance imaging fusion-targeted and systematic transrectal ultrasoundguided biopsies for detecting prostate cancer in men undergoing repeated biopsies. Urologia Internationalis. 2017;

[13] Kasivisvanathan V, Rannikko A, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. The New England Journal of Medicine. 2018;278(19):1767-1777

[14] Giganti F, Moore C. A critical comparison of techniques for MRItargeted biopsy of the prostate. Translational Andrology and Urology.

[15] Kongnyuy MM, George AKA, Rastinehad A, Pinto P. Magnetic resonance imaging-ultrasound fusionguided prostate biopsy: Review of technology, techniques, and

outcomes. Current Urology Reports.

[16] Robertson N, Emberton M, Moore C. MRI-targeted prostate biopsy: A

2017;6(3):432-443

2016;17(4):32

of Urology. 2016;196:1616-1618

99:384-391

Urology. 2016;69:41-49

[2] Wein A, Kavoussi L, Partin A, Peters C. Campbell-Walsh Urolog. 10th

[3] Valerio M, Donaldson I, Emberton M, et al. Detection of clinically significant prostate cancer using

magnetic resonance imaging-ultrasound fusion targeted biopsy: A systematic review. European Urology. 2015;68:8-19

[4] Sarkar S, Das S. A review of imaging methods for prostate cancer detection.

Computational Biology. 2016;7(S1):1-15

[5] Gayet M, van der Aa A, Beerlage HP, et al. The value of magnetic resonance imaging and ultrasonography (MRI/ US)-fusion biopsy platforms in prostate

[6] Wu J, Ji A, Xie B, et al. Is magnetic resonance/ultrasound fusion prostate biopsy better than systematic prostate biopsy? An updated meta- and trial sequential analysis. Oncotarget. 2015;

[7] Mottet NN, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. European Urology.

[8] Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS prostate imaging reporting and data system: 2015, version 2. European Urology. 2016;69:16-40

[9] Barentsz J, Weinreb J, Verma S, et al. Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic

ed. Saunders: Elsevier; 2012

Biomedical Engineering and

cancer detection: A systematic review. BJU International. 2016;117:

392-400

6(41):43571-43580

2017;71(4):618-629

resonance imaging and

145

\*Address all correspondence to: abenelli@asst-rhodense.it

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The Role of MRI-TRUS Fusion Biopsy in the Diagnosis of Clinical Significant… DOI: http://dx.doi.org/10.5772/intechopen.85243
